1613191-77-7

Basic information

• Product Name: 2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid
• CAS NO: 1613191-77-7
• Molecular Weight: 196.141
• Mol File: 1613191-77-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid(1613191-77-7)
• EPA Substance Registry System: 2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid(1613191-77-7)

Safety Data

• Hazardous Substances Data: 1613191-77-7(Hazardous Substances Data)

Usage

Structure

Pyrazolopyrimidine derivative with a carboxylic acid functional group

Utility

Building block in the synthesis of pharmaceuticals, agrochemicals, and organic compounds
Potential therapeutic agent for cancer and inflammatory diseases

Biological Activity

Inhibitory activity against certain enzymes and proteins

Applications

Biochemical research
Drug discovery

Upstream product

• 1613191-76-6 allyl 2-amino-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carboxylate 

Downstream Products

• 1613191-99-3 2-amino-6-fluoro-N-[5-fluoro-4-(4-{[4-(oxetan-3-yl)piperazin-1-yl]carbonyl}piperidin-1-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant articles and documents

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I) or a pharmaceutically acceptable salt, wherein the variables are as defined herein.